+ Site Statistics
References:
54,258,434
Abstracts:
29,560,870
PMIDs:
28,072,757
+ Search Articles
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ PDF Full Text
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Translate
+ Recently Requested

Prevalence of Active Hepatitis E Virus Infection and Efficacy of Ribavirin Treatment in Renal Allograft Recipients



Prevalence of Active Hepatitis E Virus Infection and Efficacy of Ribavirin Treatment in Renal Allograft Recipients



Transplant Infectious Disease 2019: E13088



Hepatitis E virus (HEV) genotype 3 infection frequently progresses to chronic disease with persisting HEV viremia in immunocompromised patients. Here, we evaluated the prevalence of HEV infection in renal allograft recipients and investigated the efficacy and tolerability of ribavirin monotherapy. A total of 947 recipients on average 8.7 years posttransplant were screened for anti-HEV IgG, IgM and HEV-RNA. Sixteen HEV-viremic renal allograft recipients were treated with ribavirin for 12 weeks. HEV-RNA concentration, laboratory and clinical parameters were assessed at baseline, during therapy and 12 weeks after treatment cessation. HEV-genotyping was performed in all HEV-viremic patients. Past HEV infection was detected serologically in 18% of the renal allograft recipients. Ongoing HEV replication was found in 16 recipients (all genotype 3). Unanimously, distinct HEV-sequences were revealed in all HEV-viremic patients. At start of ribavirin treatment, median HEV-RNA viral load was 4.3x106 (8000-5.0x106 ) IU/mL. 94% of HEV-infected allograft recipients showed a sustained virological response 12 weeks after treatment cessation. Ribavirin treatment was associated with rapid decrease in liver enzymes and rare occurrence of anemia. Prevalence of active HEV infection is important in renal transplant patients without signs of nosocomial infection. Ribavirin treatment was safe and effective. This article is protected by copyright. All rights reserved.

(PDF emailed within 0-6 h: $19.90)

Accession: 066641225

Download citation: RISBibTeXText

PMID: 30929308

DOI: 10.1111/tid.13088


Related references

Prevalence, morbidity, and therapy of hepatitis E virus infection in pediatric renal allograft recipients. Pediatric Nephrology 33(7): 1215-1225, 2018

Treatment of active CMV infection in renal allograft recipients with oral ganciclovir Monitoring efficacy using quantitative CMV-PCR. Journal of Investigative Medicine 49(1): 48A, 2001

Treatment of active CMV infection with oral ganciclovir in renal allograft recipients Monitoring efficacy with quantitative CMV-PCR. Journal of the American Society of Nephrology 11(Program and Abstract Issue): 719A-720A, 2000

Treatment With Grazoprevir/Elbasvir for Renal Transplant Recipients With Chronic Hepatitis C Virus Infection and Impaired Allograft Function. Transplantation Direct 5(1): E419-E419, 2019

Efficacy and safety of treatment of hepatitis C virus infection in renal transplant recipients. World Journal of Gastroenterology 18(1): 55-63, 2012

The impact of hepatitis B virus and hepatitis C virus infection on clinical outcome in renal allograft recipients. Nephrology Dialysis Transplantation 11(6): A285, 1996

Hepatitis C virus infection in renal allograft recipients. Polish Journal of Immunology 20(4): 426-429, 1995

Impact of occult hepatitis B virus infection or hepatitis B virus DNA integration on efficacy of chronic hepatitis C treatment with peginterferon and ribavirin: where are we?. Journal of Clinical Gastroenterology 48(1): 3-5, 2014

Impact of hepatitis C virus infection in renal allograft recipients. Transplantation Proceedings 32(7): 1949, 2000

The impact of hepatitis C virus infection on renal allograft recipients. Kidney International 45(1): 238-244, 1994

Clinical course of hepatitis B virus infection in renal allograft recipients. Digestive Diseases and Sciences 52(12): 3440-3443, 2007

Safety and efficacy of peginterferon-α2a plus ribavirin treatment in renal transplant recipients with chronic hepatitis C. Journal of Hepatology 58(6): 1096-1103, 2014

Prevalence and clinical features of hepatitis G virus infection in bone marrow allograft recipients. Bone Marrow Transplantation 20(11): 965-968, Dec 1, 1997

Clinicopathologic features of hepatitis C virus infection in renal allograft recipients. Transplantation 58(9): 996-1000, 1994

A prospective study of hepatitis C virus infection in renal allograft recipients. Transplantation 61(6): 886-889, 1996